Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 May 16;4(8):1170-1174.
doi: 10.1016/j.ekir.2019.04.027. eCollection 2019 Aug.

Effect of a Somatostatin Analogue on the Vasopressin Pathway in Patients With ADPKD

A Lianne Messchendorp  1 , Bart J Kramers  1 , Edwin M Spithoven  1 , Katrin Stade  2 , Esther Meijer  1 , Ron T Gansevoort  1 ; DIPAK-1 Study Investigators
Collaborators, Affiliations

Effect of a Somatostatin Analogue on the Vasopressin Pathway in Patients With ADPKD

A Lianne Messchendorp et al. Kidney Int Rep. .
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Change in 24-hour urine volume (left panel) and fractional free water clearance (right panel) from baseline to T12 in patients receiving standard care or lanreotide, stratified according to mean level of estimated glomerular filtration rate (eGFR) at baseline.
See this image and copyright information in PMC

References

    1. Ruggenenti P., Remuzzi A., Ondei P. Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease. Kidney Int. 2005;68:206–216. - PubMed
    1. van Keimpema L., Nevens F., Vanslembrouck R. Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial. Gastroenterology. 2009;137:1661–1668. - PubMed
    1. Chrispijn M., Nevens F., Gevers T.J. The long-term outcome of patients with polycystic liver disease treated with lanreotide. Aliment Pharmacol Ther. 2012;35:266–274. - PubMed
    1. Hogan M.C., Masyuk T.V., Page L. Somatostatin analog therapy for severe polycystic liver disease: results after 2 years. Nephrol Dial Transplant. 2012;27:3532–3539. - PMC - PubMed
    1. Caroli A., Perico N., Perna A. Effect of longacting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): a randomised, placebo-controlled, multicentre trial. Lancet. 2013;382:1485–1495. - PubMed

LinkOut - more resources